NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Announces Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Share on StockTwits

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.12), Morningstar.com reports. The business had revenue of $1.49 million for the quarter.

NovaBay Pharmaceuticals stock traded down $0.03 during mid-day trading on Friday, reaching $0.39. The company had a trading volume of 406,700 shares, compared to its average volume of 271,907. NovaBay Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $3.74.

NBY has been the subject of several recent analyst reports. HC Wainwright downgraded shares of NovaBay Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $1.50 price objective for the company. in a report on Wednesday, March 13th. Zacks Investment Research raised shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating and set a $1.50 price objective for the company in a report on Thursday, March 14th. Finally, Laidlaw downgraded shares of NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Tech Know Bits and is the sole property of of Tech Know Bits. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://techknowbits.com/2019/05/18/novabay-pharmaceuticals-nby-issues-quarterly-earnings-results.html.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Featured Article: Analyzing a company’s cash flow statement

Earnings History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.